AZN — AstraZeneca PLC

Is AZN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - General

Overbought As of August 19, 2026

AstraZeneca PLC (AZN) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $164.95. The rating moved from Neutral to Overbought on August 19, 2026.

See all overbought Healthcare stocks →

AI analysis

AstraZeneca PLC (AZN) benefits from a diversified, large-cap commercial footprint and a strong biologics and oncology pipeline that underpin steady cash flow and the ability to invest in R&D and selective M&A. Recent sector themes (biologics/GLP-1 demand, CRO/CDMO strength and elevated pharma M&A multiples) are constructive for near- to medium-term growth, while defensive sector interest supports valuation stability. Near-term market commentary and social signals are neutral-to-slightly positive, with no material macro or geopolitical shocks in the recent window. Key risks include payer-driven margin pressure, potential clinical or regulatory setbacks, competition, and operational/supply constraints. The balance of durable cash generation, pipeline optionality, and sector tailwinds suggests upside over the next month, tempered by the listed execution and regulatory risks that warrant monitoring.

Key factors

  • Diversified product portfolio with strong oncology and biologics franchises providing stable revenue and margin support
  • Robust cash flow generation and scale that enable continued R&D investment and selective M&A at attractive valuations
  • Exposure to GLP-1 / biologics and CRO/CDMO demand tailwinds that can drive upside in biologics-related revenues and partnerships
  • Global footprint and established commercial presence in developed markets that help defend pricing and distribution
  • Elevated M&A multiples across biotech/pharma creating an acquisitive backdrop that could accelerate pipeline replenishment or bolt-on deals
  • Market sentiment steady with limited short-term macro disruption, allowing fundamentals and pipeline updates to drive moves

Risks

  • Payer pricing pressure and strategic rationalization of Medicare Advantage and pharmacy distribution that could compress margins or slow uptake
  • Clinical trial setbacks or regulatory delays across key pipeline programs that would materially affect forward growth expectations
  • Increased competition in key therapeutic areas (e.g., oncology, GLP-1 biologics) from large peers and innovative entrants
  • Macroeconomic or FX volatility that can depress reported results and investor appetite for cyclically exposed pharma names
  • Litigation, patent expiries, or pricing reforms in major markets that could erode revenue visibility
  • Reliance on third-party CRO/CDMO capacity could create supply bottlenecks or cost pressure if demand outstrips capacity

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for AZN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.